SRRK

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 46.82 USD with a low forecast of 42.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Scholar Rock Holding Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Scholar Rock Holding Corp. EPS for the last quarter amounts to -0.90 USD, increased 36.36 % YoY.

Scholar Rock Holding Corp (SRRK) has 196 emplpoyees as of December 15 2025.

Today SRRK has the market capitalization of 4.78B USD.